Drug-induced cholestasis

Clinics in Liver Disease

Volumn 7, Issue 2, 2003, Pages 311-330

  Levy, Cynthia ^a   Lindor, Keith D ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; AZATHIOPRINE; COLESTYRAMINE; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPHENHYDRAMINE; ERYTHROMYCIN; ESTROGEN; FLUCLOXACILLIN; HERBACEOUS AGENT; HISTAMINE H1 RECEPTOR ANTAGONIST; HYDROXYZINE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MESALAZINE; NALOXONE; NEUROLEPTIC AGENT; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OCTREOTIDE; ORAL ANTIDIABETIC AGENT; ORAL CONTRACEPTIVE AGENT; OXACILLIN; PHENOBARBITAL; RIFAMPICIN; SULINDAC; UNINDEXED DRUG; URSODEOXYCHOLIC ACID;

ANTIBIOTIC THERAPY; BILE DUCT DISEASE; CHINESE MEDICINE; CHOLELITHIASIS; CHOLESTASIS; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; CROSSOVER PROCEDURE; DETOXIFICATION; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG INDUCED DISEASE; ENZYME INDUCTION; HERBAL MEDICINE; HUMAN; HYPERBILIRUBINEMIA; JAUNDICE; LIVER BIOPSY; LIVER FAILURE; LIVER TOXICITY; LIVER TRANSPLANTATION; MYOCARDITIS; NEPHROTOXICITY; ORAL CONTRACEPTION; PANCREATITIS; PERICARDITIS; PROGNOSIS; PRURITUS; REVIEW; SYNDROME DELINEATION; TOXIC HEPATITIS; VANISHING BILE DUCT SYNDROME;

EID: 0038385419     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1089-3261(03)00032-1     Document Type: Review

References (79)

1. Friis H, Andreasen PB. Drug-induced hepatic injury: an analysis of 1100 cases reported to the Danish Committee on Adverse Drug Reactions between 1978 and 1987. J of Intern Med 1992;232:133-8.
2. Lewis JH. Drug-induced liver disease. Med Clin N Am 2000;84:1275-311.
3. Maldonado O, Demasi R, Maldonado Y, et al. Extremely high levels of alkaline phosphatase in hospitalized patients. J Clin Gastroenterol 1998;27:342-5.
4. Lewis JH, Zimmerman HJ. Drug- and Chemical-Induced Cholestasis. Clin Liver Dis 1999;3:433-64.
5. Benichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 1990;11:272-6.
6. Erlinger S. Drug-induced cholestasis. J Hepatol 1997;26:1-4.
7. Zimmerman HJ, Ishak KG. General aspects of drug-induced liver disease. Gastroenterol Clin North Am 1995;24:739-57.
8. Chitturi S, Farrell GC. Drug-Induced Cholestasis. Semin Gastrointest Dis 2001;12:113-24.
9. Reddy KR, Brillant P, Schiff ER. Amoxicillin-clavulanate potassium-associated cholestasis. Gastroenterology 1989;96:1135-41.
10. Geubel AP, Sempoux CL. Drug and toxin-induced bile duct disorders. J Gastroenterol Hepatol 2000;15:1232-8.
11. Srivastava M, Perez-Atayde A, Jonas MM. Drug-associated acute-onset vanishing bile duct and Stevens-Johnson syndromes in a child. Gastroenterology 1998;115:743-6.
12. Lewis JH. NSAID-induced hepatotoxicity. Clinics in Liver Disease 1998;2:543-61.
13. van't Wout JW, Herrmann WA, de Vries RA, et al. Terbinafine-associated hepatic injury. J Hepatol 1994;21:115-7.
14. Ishak KG. Drug-induced liver injury pathology in AASLD postgraduate course 1998. Clinical and pathological correlations in liver disease. Approaching the next millennium. Washington DC: 1998.
15. Degott C, Feldman G, Larrey D, et al. Drug-induced prolonged cholestasis in adults: a histological semiquantitative study demonstrating progressive ductopenia. Hepatology 1992;15:244-51.
16. Ludwig J, Wiesner RH, LaRusso NF. Idiopathic adulthood ductopenia: a cause of chronic cholestatic liver disease and biliary cirrhosis. J Hepatol 1988;7:193-9.
17. Ludwig J. Idiopathic adulthood ductopenia: an update. Mayo Clin Proc 1998;73:285-91.
18. Desmet V. Vanishing bile duct syndrome in drug-induced liver disease. J Hepatol 1997;26:31-5.
19. Larrey D, Erlinger S. Drug-induced cholestasis. Baillieres Clin Gastroenterol 1988;2:423-52.
20. Babbs C, Warnes TW. Primary biliary cirrhosis after benoxaprofen. BMJ 1986;203:241-2.
21. Lazarczyk DA, Duffy MC. Erythromycin-induced primary biliary cirrhosis. Dig Dis Sci 2000;45:1115-8.
22. Alpini G, Lenzi R, Sarkozi L, et al. Biliary physiology in rats with bile ductular cell hyperplasia: evidence for a secretory function of proliferated bile ductules. J Clin Invest 1988;81:569-78.
23. Yamada S, Howe S, Scheuer PJ. Three-dimensional reconstruction of biliary pathways in primary cirrhosis: a computer-assisted study. J Pathol 1987;152:317-23.
24. Hohn D, Melnick J, Stagg R, et al. Biliary sclerosis in patients receiving hepatic arterial infusions of floxuridine. J Clin Oncol 1985;3:98-102.
25. Ludwig J, Kim CH, Wiesner RH. Floxuridine-induced sclerosing cholangitis: An ischemic cholangiopathy. Hepatology 1989;9:215-22.
26. Castellano G, Moreno-Sanchez D, Gutierrez J, et al. Caustic sclerosing cholangitis. Report of four cases and a cumulative review of the literature. Hepatogastroenterology 1994;41:458-70.
27. Riccabona M, Kerbl R, Schwinger W, et al. Ceftriaxone-induced cholelithiasis - a harmless side-effect? Klin Padiatr 1993;205:421-3.
28. Zinberg J, Chernaik R, Coman E, et al. Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis. Am J Gastroenterol 1991;86:1251-4.
29. Sautereau DC, Moesch C. Occurrence of biliary drug lithiasis due to dipyridamole. Endoscopy 1997;29:421-3.
30. Sheehan MT, Nippoldt TB. Hepatolithiasis (intrahepatic stone) during octreotide therapy for acromegaly: a case report. Pituitary 2000;3:227-30.
31. DeLeve LD, Kaplowitz N. Mechanisms of drug-induced liver disease. Gastroenterol Clin North Am 1995;24:787-810.
32. Trauner M, Meier PJ, Boyer JL. Molecular pathogenesis of cholestasis. N Engl J Med 1998;339:1217-27.
33. Stieger B, Fattinger K, Madon J, et al. Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology 2000;118:422-30.
34. Bissell DM, Gores GJ, Laskin DL, et al. Drug-Induced Liver Injury: Mechanisms and Test Systems. Hepatology 2001;33:1009-13.
35. Jaeschke H, Gores GJ, Cederbaum AI, et al. Mechanisms of Hepatotoxicity. Toxicol Sci 2002;65:166-76.
36. O'Donohue J, Oien KA, Donaldson P. Co-amoxi-clav jaundice: clinical and histological features and HLA class II association. Gut 2000;47:717-20.
37. Lindberg MC. Hepatobiliary complications of oral contraceptives. J Gen Intern Med 1992;7:199-209.
38. Richardet JP, Mallat A, Zafrani ES, et al. Prolonged cholestasis with ductopenia after administration of amoxicillin-clavulanic acid. Dig Dis Sci 1999;44:1997-2000.
39. Garcia Rodriguez LA, Stricker BH, Zimmerman HJ. Risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid. Arch Intern Med 1996;156:1327-32.
40. Carson JL, Strom BL, Duff A, et al. Acute liver disease associated with erythromycins, sulfonamides and tetracyclines. Ann Intern Med 1993;119:576-83.
41. Brown RA. Two cases of untoward reaction after Ilosone. BMJ 1963;2:913-4.
42. Farrell GC. Drug-induced liver disease. Edinburgh: Churchill Livingstone; 1994.
43. Tauris P, Jorgensen NF, Petersen CM, et al. Prolonged severe cholestasis induced by oxacillin derivatives. A report of two cases. Acta Med Scand 1985;217:567-9.
44. Lakehal F, Dansette PM, Becquemont L, et al. Indirect cytotoxicity of flucloxacillin toward human biliary epithelium via metabolite formation in hepatocytes. Chem Res Toxicol 2001;14:694-701.
45. Van Steenbergen W, Peters P, De Bondt J, et al. Nimesulide-induced acute hepatitis: evidence from six cases. J Hepatol 1998;29:135-41.
46. Tarazi EM, Harter JG, Zimmerman HJ, et al. Sulindac-associated hepatic injury: Analysis of 91 cases reported to the Food and Drug Administration. Gastroenterology 1993;104:569-74.
47. Bolder U, Trang NV, Hagey LR, et al. Sulindac is excreted into bile by a canalicular bile salt pump and undergoes a cholehepatic circulation in rats. Gastroenterology 1999;117:962-71.
48. Stoschus B, Meybehm M, Spengler U, et al. Cholestasis associated with mesalazine therapy in a patient with Crohn's disease. J Hepatol 1997;26:425-8.
49. Menguini VV, Arora AS. Infliximab-Associated Reversible Cholestatic Liver Disease. Mayo Clin Proc 2001;76:84-6.
50. Veysey MJ, Thomas LA, Mallet AI, et al. Prolonged large bowel transit increases serum deoxycholic acid: a risk factor for octreotide-induced gallstones. Gut 1999;44:675-81.
51. Morales JM. Drug-induced hepatotoxicity. N Engl J Med 1996;334:863-4.
52. Moradpour D, Altofer J, Flury R, et al. Chlorpromazine-induced vanishing bile duct syndrome leading to biliary cirrhosis. Hepatology 1994;20:1437-41.
53. Krebs S, Dormann H, Muth-Selbach U, et al. Risperidone-induced cholestatic hepatitis. Eur J Gastroenterol Hepatol 2001;13:67-9.
54. Nunes A, Amaro P, Macoas F, et al. Fosinopril-induced prolongued cholestatic jaundice and pruritus: first case report. Eur J Gastroentcrol Hepatol 2001;13:279-82.
55. Schiff ER. Uptade in hepatology. Ann Intern Med 2000;132:460-6.
56. Gitlin N, Julie NL, Spurr CL, et al. Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone. Ann Intern Med 1998;129:36-8.
57. Ramanathan M, Wahunuddin S, Kew ST. Glibenclamide induced chronic cholestasis simulating primary biliary cirrhosis: a case report. Med J Malaysia 1996;51:140-3.
58. Fong DG, Angulo P, Burgart LJ, et al. Cetirizine-Induced Cholestasis. J Clin Gastroenterol 2000;31:250-3.
59. Batchelor WB, Heathcote J, Wanless IR. Chaparral-inducel hepatic injury. Am J Gastroenterol 1995;90:831-3.
60. Gordon D, Rosenthal G, Hart J, et al. Chaparral ingestion: the broadening spectrum of liver injury caused by herbal medications. JAMA 1995;273:489-90.
61. Sheikh N, Philen R, Love L. Chaparral-associated hepatotoxicity. Arch Intern Med 1997;157:913-9.
62. Nadir A, Reddy D, Van Thiel DH. Cascara sagrada-induced intrahepatic cholestasis causing portal hypertension: case report and review of herbal hepatotoxicity. Am J Gastroenterol 2000;95:3634-7.
63. Rosengren JE, Aberg T. Cleansing the colon without enemas. Radiologe 1975;15:421-6.
64. Marchesi M, Marcato M, Silvestrini C. Clinical experience with a preparation containing cascara sagrada and boldo in the therapy of simple constipation in the elderly. G Clin Med 1982;63:850-63.
65. Roberts JE, Tyler VE. Tyler's herbs of choice: the therapeutic use of phytomedicinals. Binghamton (NY): The Haworth Herbal Press; 1999. p. 59.
66. Giavina-Bianchi PFJ, Castro FF, Machado ML, et al. Occupational respiratory allergic disease induced by Passiflora alata and Rhamnus purshiana. Annals of Allergy, Asthma, & Immunology 1997;79:449-54.
67. Woolf GM, Rojter SE, Villamil FG, et al. Leads from the Morbidity and Mortality Report, Atlanta, GA: Jin Bu Huan Toxicity in Adults - Los Angeles, 1993. JAMA 1994;271:423-4.
68. Horowitz RS, Feldhaus K, Dart RC, et al. The clinical spectrum of Jin Bu Huan. Arch Intern Med 1996;156:899-903.
69. Picciotto A, Campo N, Brizzolara R, et al. Chronic hepatitis induced by Jin Bu Huan. J Hepatol 1998;28:165-7.
70. Woolf GM, Petrovic LM, Rojter SE, et al. Acute hepatitis associated with the Chinese herbal product Jin Bu Huan. Ann Intern Med 1994;121:729-35.
71. Aithal PG, Day CP. The natural history of histologically proved drug induced liver disease. Gut 1999;44:731-5.
72. Raiford DS. Priritus of chronic cholestasis. QJM 1995;88:603-7.
73. Lazaridis KN, Gores GJ, Lindor KD. Ursodeoxycholic Acid "Mechanisms of Action and Clinical Use in Hepatobiliary Disorders." J Hepatol 2001;35:134-46.
74. O'Brien CB, Shields DS, Saul SH, et al. Drug-induced vanishing bile duct syndrome: response to ursodiol. Am J Gastroenterol 1996;91:1456-7.
75. Bachs L, Pares A, Montserrat E, et al. Effects of long term rifampicin administration in primary biliary cirrhosis. Gastroenterology 1992;102:2077-80.
76. Bloomer JR, Boyer JL. Phenobarbital effects in cholestatic liver disease. Ann Intern Med 1975;82:310-7.
77. Bergasa NV, Alling DW, Talbot TL, et al. Effects of Naloxone Infusions in patients with the pruritus of cholestasis: a double-blind, randomized, controlled trial. Ann Intern Med 1995;123:161-7.
78. Wolfhagen FH, Sternieri E, Hop WC, et al. Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo controlled study. Gastroenterology 1997;113:1264-9.
79. Raderer M, Muller C, Scheithauner W. Ondansetron for pruritus due to cholestasis [letter]. N Engl J Med 1994;330:1540.